Search research articles
Contact Us
Filters
Showing results (51-60 of 91) with videos related to
Page
of 10
Sort By:
Psychiatry (Edgmont (Pa. : Township))
|
December 24, 2010
Use of antipsychotics in the treatment of post-traumatic stress disorder
Babatunde Adetunji, Maju Mathews, Adedapo Williams, et al.
Neuropsychiatric Disease and Treatment
|
May 8, 2018
Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
Huafang Li, Yan Li, Yu Feng, et al.
Neuropsychiatric Disease and Treatment
|
August 18, 2017
Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
Suresh Durgam, Ronald P Landbloom, Mary Mackle, et al.
Epidemiology and Psychiatric Sciences
|
April 30, 2020
Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui
Maju Mathews, Ella J Daly, Vanina Popova, et al.
International Clinical Psychopharmacology
|
August 21, 2015
Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study
Carl Gommoll, Giovanna Forero, Maju Mathews, et al.
Neuropsychiatric Disease and Treatment
|
December 31, 2020
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia
Martin Lambert, Pedro Sanchez, Paul Bergmans, et al.
Clinical Drug Investigation
|
June 9, 2018
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis
Maju Mathews, Huiling Pei, Adam Savitz, et al.
NPJ Schizophrenia
|
July 29, 2017
Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
Srihari Gopal, Haiyan Xu, Kelly McQuarrie, et al.
Journal of Psychiatric Practice
|
April 7, 2007
Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis
Harun Evcimen, Yesne Alici-Evcimen, Biju Basil, et al.
Journal of Clinical Psychopharmacology
|
February 28, 2019
Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study
John M Kane, Christoph U Correll, Nicholas Delva, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 91) with videos related to
Sort By:
Page
of 10
Psychiatry (Edgmont (Pa. : Township))
|
December 24, 2010
Use of antipsychotics in the treatment of post-traumatic stress disorder
Babatunde Adetunji, Maju Mathews, Adedapo Williams, et al.
Neuropsychiatric Disease and Treatment
|
May 8, 2018
Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
Huafang Li, Yan Li, Yu Feng, et al.
Neuropsychiatric Disease and Treatment
|
August 18, 2017
Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
Suresh Durgam, Ronald P Landbloom, Mary Mackle, et al.
Epidemiology and Psychiatric Sciences
|
April 30, 2020
Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui
Maju Mathews, Ella J Daly, Vanina Popova, et al.
International Clinical Psychopharmacology
|
August 21, 2015
Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study
Carl Gommoll, Giovanna Forero, Maju Mathews, et al.
Neuropsychiatric Disease and Treatment
|
December 31, 2020
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia
Martin Lambert, Pedro Sanchez, Paul Bergmans, et al.
Clinical Drug Investigation
|
June 9, 2018
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis
Maju Mathews, Huiling Pei, Adam Savitz, et al.
NPJ Schizophrenia
|
July 29, 2017
Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
Srihari Gopal, Haiyan Xu, Kelly McQuarrie, et al.
Journal of Psychiatric Practice
|
April 7, 2007
Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis
Harun Evcimen, Yesne Alici-Evcimen, Biju Basil, et al.
Journal of Clinical Psychopharmacology
|
February 28, 2019
Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study
John M Kane, Christoph U Correll, Nicholas Delva, et al.
Page
of 10